Preliminary experience with Norplant® in an inner city population

Vanessa E. Cullins, Paul D. Blumenthal, Robin E. Remsburg, George R. Huggins

Research output: Contribution to journalArticle

Abstract

Norplant®, the five-year subdermal contraceptive system, is the first implantable contraceptive method approved for general use in the United States. We describe the preliminary experiences of 246 U.S. women who accepted Norplant between April, 1991 and September, 1991. Norplant was well accepted among this diverse general population. Intensive counselling about side effects, especially menstrual changes, is crucial for patient satisfaction. Although 48% of acceptors experienced menstrual cycle changes and 70% experienced at least one side effect, phone calls and unscheduled visits for problems were infrequent. Adequate counselling about side effects obviates the need for a routine follow-up visit one month after insertion.

Original languageEnglish (US)
Pages (from-to)193-203
Number of pages11
JournalContraception
Volume47
Issue number2
DOIs
Publication statusPublished - 1993

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this